Molecular surveillance for carbapenemase genes in carbapenem resistant Pseudomonas aeruginosa in Australian patients with cystic fibrosis
References (35)
- et al.
Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study
Lancet Infect Dis
(2013) - et al.
Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis
J Cystic Fibrosis
(2008) - et al.
Pseudomonas aeruginosa infection in cystic fibrosis caused by an epidemic metallo-beta-lacta-mase-producing clone with a heterogeneous carbapenem resistance phenotype
Clin Microbiol Infect
(2011) - et al.
Metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa isolates from a cystic fibrosis patient
Int J Antimicrob Agents
(2008) - et al.
High prevalence of a class 1 integron-associated aadB gene cassette in Pseudomonas aeruginosa isolates from an Australian cystic fibrosis patient population
Pathology
(2008) - et al.
A simple approach for preparing real-time PCR positive reaction controls for rare or emerging viruses
J Clin Virol
(2010) - et al.
Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time and high-resolution melting curve analysis
Clin Microbiol Infect
(2011) - et al.
Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues
Int J Antimicrob Agents
(2007) Pseudomonas aeruginosa: resistance to the max
Front Microbiol
(2011)- et al.
Genetic and biochemical characterization an acquired subgroup B3 metallo-beta-lactamase gene, blaAIM-1, and its unique genetic context in Pseudomonas aeruginosa from Australia
Antimicrob Agents Chemother
(2012)
Isolation of NDM-1-producing Pseudomonas aeruginosa sequence type ST235 from a stem cell transplant patient in Italy, May 2013
Euro Surveill
Emergence of metallo-beta-lactamases GIM-1 and VIM in multidrug-resistant Pseudomonas aeruginosa in North Rhine-Westphalia, Germany
J Antimicrob Chemother
Large outbreak of infection and colonization with gram-negative pathogens carrying the metallo-beta-lactamase gene blaIMP-4 at a 320-bed tertiary hospital in Australia
Infect Control Hosp Epidemiol
Outbreak of carbapenemresistant Pseudomonas aeruginosa producing SPM-1 metallo-{beta}-lacta-mase in a teaching hospital in southern Brazil
J Antimicrob Chemother
Emergence of KPC-producing Pseudomonas aeruginosa in the United States
Antimicrob Agents Che-mother
Population-based epidemio-logical study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains
J Infect Dis
Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia
Clin Infect Dis
Cited by (9)
Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis
2022, Journal of Cystic FibrosisCitation Excerpt :Therefore, meropenem resistance is a polygenic trait [14], and more diverse collections of clinical isolates are needed to identify the genes that are associated with this phenotype. Other mechanisms contributing to carbapenem resistance include the production of antibiotic-inactivating carbapenemases; but studies in CF P. aeruginosa isolates suggest that this mechanism is uncommon [10,15]. Upregulation of multi-drug efflux pumps and mutations in a multitude of regulatory genes may also contribute to increased MICs, which highlights the complexity of P. aeruginosa AMR [14].
Finding the relevance of antimicrobial stewardship for cystic fibrosis
2020, Journal of Cystic FibrosisThe potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways
2017, Journal of Cystic FibrosisCitation Excerpt :Recent expert reviews suggest that deaths due to antimicrobial resistant infections will cause more deaths than cancer in coming decades [14] and are a dire warning to the world that we must increase our capacity to produce new classes of antimicrobial therapies. In CF, the resistance of P. aeruginosa isolates to traditional antimicrobials is increasing in both the United States and Australia [15,16]. There are several novel treatment options for P. aeruginosa and other bacterial infections both in CF and in wider bacterial disease contexts, which are at various stages of investigation.
Evaluation of phenotypic screening tests for carbapenemase production in Pseudomonas aeruginosa from patients with cystic fibrosis
2015, Journal of Microbiological MethodsMobile Carbapenemase Genes in Pseudomonas aeruginosa
2021, Frontiers in Microbiology